Duhay, director at enVVeno, sells $4k in NVNO stock

Director Francis Duhay of enVVeno Medical Corp (NASDAQ:NVNO), a micro-cap company with a market value of $17.53 million, sold 4,900 shares of common stock on September 15, 2025, for approximately $4,067.

The shares were sold at a weighted-average price of $0.83, with individual sales prices ranging from $0.8205 to $0.84. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025. Following the transaction, Duhay directly owns 97,444 shares of enVVeno Medical Corp. The stock, which InvestingPro analysis indicates is currently undervalued, has shown significant volatility, dropping 69% year-to-date but surging 26% in the past week. Get access to 13 additional exclusive ProTips and comprehensive analysis with InvestingPro.

In other recent news, enVVeno Medical Corporation received a not-approvable letter from the U.S. Food and Drug Administration for its VenoValve device, designed to treat severe deep chronic venous insufficiency. The FDA stated that the clinical improvement data provided was insufficient to establish a favorable benefit-risk profile for the device. In response, enVVeno Medical plans to file a supervisory appeal to challenge this decision before the September 18 deadline. Preliminary findings from a health economic study conducted by the company indicate that the VenoValve could be a cost-effective treatment option, showing cost savings of $32,442 per patient over five years. The study also highlighted the prevention of 2.2 venous ulcers per patient and 0.33 additional quality-adjusted life years gained per patient. Despite the FDA’s decision, these findings suggest potential advantages over standard care treatments. The company’s stock experienced a significant decline following the FDA’s rejection. These developments are part of enVVeno Medical’s ongoing efforts to bring VenoValve to market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.